Marker Therapeutics, акция обыкновенная (US57055L2060, MRKR, GX1, MRKR.P)

Marker Therapeutics, Inc., formerly known as TapImmune, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.

• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Чистый долг / EBITDA
• Выручка
• Рентабельность по EBITDA (%)
• Общий долг / Капитал